Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H29NO10 |
Molecular Weight | 527.5199 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(C[C@@](O)(CC2=C(O)C3=C(C(=O)C4=C(C=CC=C4OC)C3=O)C(O)=C12)C(C)=O)O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5
InChI
InChIKey=STQGQHZAVUOBTE-VGBVRHCVSA-N
InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1
Molecular Formula | C27H29NO10 |
Molecular Weight | 527.5199 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugs.com/dosage/daunorubicin.htmlCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22260166 | https://www.ncbi.nlm.nih.gov/pubmed/7932544 | https://www.ncbi.nlm.nih.gov/pubmed/13146115 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050467s070lbl.pdf
Sources: https://www.drugs.com/dosage/daunorubicin.html
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22260166 | https://www.ncbi.nlm.nih.gov/pubmed/7932544 | https://www.ncbi.nlm.nih.gov/pubmed/13146115 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050467s070lbl.pdf
Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer. Specifically, it is used for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. Similar to doxorubicin, daunorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis. This inhibits the progression of the enzyme topoisomerase II, which relaxes supercoils in DNA for transcription. Daunorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication. On binding to DNA, daunomycin intercalates, with its daunosamine residue directed toward the minor groove. It has the highest preference for two adjacent G/C base pairs flanked on the 5' side by an A/T base pair. Daunorubicin should only be administered in a rapid intravenous infusion. It should not be administered intramuscularly or subcutaneously, since it may cause extensive tissue necrosis. It should also never be administered intrathecally (into the spinal canal), as this will cause extensive damage to the nervous system and may lead to death.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1806 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22260166 |
|||
Target ID: CHEMBL1781 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7932544 |
|||
Target ID: CHEMBL3004 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9647783 |
70.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CERUBIDINE Approved UseDaunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. Launch Date3.14409615E11 |
|||
Primary | CERUBIDINE Approved UseDaunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. Launch Date3.14409615E11 |
|||
Primary | CERUBIDINE Approved UseDaunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. Launch Date3.14409615E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
26 μg/mL |
44 mg/m² 1 times / 2 days multiple, intravenous dose: 44 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: Cytarabine |
DAUNORUBICIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
637 μg × h/mL |
44 mg/m² 1 times / 2 days multiple, intravenous dose: 44 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: Cytarabine |
DAUNORUBICIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
31.5 h |
44 mg/m² 1 times / 2 days multiple, intravenous dose: 44 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: Cytarabine |
DAUNORUBICIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3% |
DAUNORUBICIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
190 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 190 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 190 mg/m2, 1 times / 3 weeks Sources: Page: p.573, 575 |
unhealthy, 10 n = 6 Health Status: unhealthy Condition: Cancer Age Group: 10 Sex: M+F Population Size: 6 Sources: Page: p.573, 575 |
DLT: Neutropenia, Leucopenia... Dose limiting toxicities: Neutropenia (grade 4, 100%) Sources: Page: p.573, 575Leucopenia (grade 4, 100%) Thrombocytopenia (grade 4, 16.7%) Anemia (grade 4, 16.7%) |
155 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 155 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 155 mg/m2, 1 times / 3 weeks Sources: Page: p.573, 575 |
unhealthy, 10 n = 6 Health Status: unhealthy Condition: Cancer Age Group: 10 Sex: M+F Population Size: 6 Sources: Page: p.573, 575 |
DLT: Neutropenia, Leucopenia... Disc. AE: Cardiac failure... Dose limiting toxicities: Neutropenia (grade 4, 100%) AEs leading toLeucopenia (grade 4, 50%) discontinuation/dose reduction: Cardiac failure (grade 5, 16.7%) Sources: Page: p.573, 575 |
50 mg/m2 1 times / 4 weeks multiple, intravenous Recommended Dose: 50 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 50 mg/m2, 1 times / 4 weeks Sources: Page: p.11 |
unhealthy, 27-87 n = 239 Health Status: unhealthy Condition: Ovarian Cancer Age Group: 27-87 Sex: M+F Population Size: 239 Sources: Page: p.11 |
Disc. AE: Skin toxicity... AEs leading to discontinuation/dose reduction: Skin toxicity (4.2%) Sources: Page: p.11 |
20 mg/m2 1 times / 2 weeks multiple, intravenous Recommended Dose: 20 mg/m2, 1 times / 2 weeks Route: intravenous Route: multiple Dose: 20 mg/m2, 1 times / 2 weeks Sources: Page: p.11 |
unhealthy, 38.7 n = 705 Health Status: unhealthy Condition: AIDS-related Kaposi’s sarcoma Age Group: 38.7 Sex: M+F Population Size: 705 Sources: Page: p.11 |
Disc. AE: Skin eruption... AEs leading to discontinuation/dose reduction: Skin eruption (0.9%) Sources: Page: p.11 |
80 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 80 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 80 mg/m2, 1 times / 3 weeks Co-administed with:: vincristine, i.v(1.4 mg/m2, day 1) Sources: Page: p.795dexamethasone, p.o(40 mg/day, days 1–4 and 9–12) |
unhealthy, 60 n = 3 Health Status: unhealthy Condition: Multiple myeloma Age Group: 60 Sex: M+F Population Size: 3 Sources: Page: p.795 |
|
100 mg/m2 1 times / 3 weeks multiple, intravenous Studied dose Dose: 100 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / 3 weeks Co-administed with:: vincristine, i.v(1.4 mg/m2, day 1) Sources: Page: p.795dexamethasone, p.o(40 mg/day, days 1–4 and 9–12) |
unhealthy, 60 n = 3 Health Status: unhealthy Condition: Multiple myeloma Age Group: 60 Sex: M+F Population Size: 3 Sources: Page: p.795 |
DLT: Acute diverticular perforation... Dose limiting toxicities: Acute diverticular perforation Sources: Page: p.795 |
100 mg/m2 1 times / 3 weeks multiple, intravenous Studied dose Dose: 100 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / 3 weeks Co-administed with:: dexamethasone, p.o(40 mg/day, days 1–4) Sources: Page: p.2648 |
unhealthy, 63 n = 38 Health Status: unhealthy Condition: Multiple myeloma Age Group: 63 Sex: M+F Population Size: 38 Sources: Page: p.2648 |
Disc. AE: Ejection fraction decreased, Prolonged neutropenia... Other AEs: Granulocytopenia, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Ejection fraction decreased (5.3%) Other AEs:Prolonged neutropenia (2.6%) Granulocytopenia (grade 4, 21%) Sources: Page: p.2648Thrombocytopenia (grade 4, 8%) Febrile neutropenia (grade 4, 11%) |
50 mg/m2 1 times / 4 weeks multiple, intravenous Recommended Dose: 50 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 50 mg/m2, 1 times / 4 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Ovarian Cancer Sources: Page: p.1 |
Disc. AE: Infusion related reaction, Myelosuppression... AEs leading to discontinuation/dose reduction: Infusion related reaction (acute) Sources: Page: p.1Myelosuppression (severe) Cardiotoxicity Congestive heart failure Hepatic impairment Reaction anaphylactic anaphylactoid (grade 3-5) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Leucopenia | grade 4, 100% DLT |
190 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 190 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 190 mg/m2, 1 times / 3 weeks Sources: Page: p.573, 575 |
unhealthy, 10 n = 6 Health Status: unhealthy Condition: Cancer Age Group: 10 Sex: M+F Population Size: 6 Sources: Page: p.573, 575 |
Neutropenia | grade 4, 100% DLT |
190 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 190 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 190 mg/m2, 1 times / 3 weeks Sources: Page: p.573, 575 |
unhealthy, 10 n = 6 Health Status: unhealthy Condition: Cancer Age Group: 10 Sex: M+F Population Size: 6 Sources: Page: p.573, 575 |
Anemia | grade 4, 16.7% DLT |
190 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 190 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 190 mg/m2, 1 times / 3 weeks Sources: Page: p.573, 575 |
unhealthy, 10 n = 6 Health Status: unhealthy Condition: Cancer Age Group: 10 Sex: M+F Population Size: 6 Sources: Page: p.573, 575 |
Thrombocytopenia | grade 4, 16.7% DLT |
190 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 190 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 190 mg/m2, 1 times / 3 weeks Sources: Page: p.573, 575 |
unhealthy, 10 n = 6 Health Status: unhealthy Condition: Cancer Age Group: 10 Sex: M+F Population Size: 6 Sources: Page: p.573, 575 |
Neutropenia | grade 4, 100% DLT |
155 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 155 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 155 mg/m2, 1 times / 3 weeks Sources: Page: p.573, 575 |
unhealthy, 10 n = 6 Health Status: unhealthy Condition: Cancer Age Group: 10 Sex: M+F Population Size: 6 Sources: Page: p.573, 575 |
Leucopenia | grade 4, 50% DLT |
155 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 155 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 155 mg/m2, 1 times / 3 weeks Sources: Page: p.573, 575 |
unhealthy, 10 n = 6 Health Status: unhealthy Condition: Cancer Age Group: 10 Sex: M+F Population Size: 6 Sources: Page: p.573, 575 |
Cardiac failure | grade 5, 16.7% Disc. AE |
155 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 155 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 155 mg/m2, 1 times / 3 weeks Sources: Page: p.573, 575 |
unhealthy, 10 n = 6 Health Status: unhealthy Condition: Cancer Age Group: 10 Sex: M+F Population Size: 6 Sources: Page: p.573, 575 |
Skin toxicity | 4.2% Disc. AE |
50 mg/m2 1 times / 4 weeks multiple, intravenous Recommended Dose: 50 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 50 mg/m2, 1 times / 4 weeks Sources: Page: p.11 |
unhealthy, 27-87 n = 239 Health Status: unhealthy Condition: Ovarian Cancer Age Group: 27-87 Sex: M+F Population Size: 239 Sources: Page: p.11 |
Skin eruption | 0.9% Disc. AE |
20 mg/m2 1 times / 2 weeks multiple, intravenous Recommended Dose: 20 mg/m2, 1 times / 2 weeks Route: intravenous Route: multiple Dose: 20 mg/m2, 1 times / 2 weeks Sources: Page: p.11 |
unhealthy, 38.7 n = 705 Health Status: unhealthy Condition: AIDS-related Kaposi’s sarcoma Age Group: 38.7 Sex: M+F Population Size: 705 Sources: Page: p.11 |
Acute diverticular perforation | DLT, Disc. AE | 100 mg/m2 1 times / 3 weeks multiple, intravenous Studied dose Dose: 100 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / 3 weeks Co-administed with:: vincristine, i.v(1.4 mg/m2, day 1) Sources: Page: p.795dexamethasone, p.o(40 mg/day, days 1–4 and 9–12) |
unhealthy, 60 n = 3 Health Status: unhealthy Condition: Multiple myeloma Age Group: 60 Sex: M+F Population Size: 3 Sources: Page: p.795 |
Prolonged neutropenia | 2.6% Disc. AE |
100 mg/m2 1 times / 3 weeks multiple, intravenous Studied dose Dose: 100 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / 3 weeks Co-administed with:: dexamethasone, p.o(40 mg/day, days 1–4) Sources: Page: p.2648 |
unhealthy, 63 n = 38 Health Status: unhealthy Condition: Multiple myeloma Age Group: 63 Sex: M+F Population Size: 38 Sources: Page: p.2648 |
Ejection fraction decreased | 5.3% Disc. AE |
100 mg/m2 1 times / 3 weeks multiple, intravenous Studied dose Dose: 100 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / 3 weeks Co-administed with:: dexamethasone, p.o(40 mg/day, days 1–4) Sources: Page: p.2648 |
unhealthy, 63 n = 38 Health Status: unhealthy Condition: Multiple myeloma Age Group: 63 Sex: M+F Population Size: 38 Sources: Page: p.2648 |
Febrile neutropenia | grade 4, 11% | 100 mg/m2 1 times / 3 weeks multiple, intravenous Studied dose Dose: 100 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / 3 weeks Co-administed with:: dexamethasone, p.o(40 mg/day, days 1–4) Sources: Page: p.2648 |
unhealthy, 63 n = 38 Health Status: unhealthy Condition: Multiple myeloma Age Group: 63 Sex: M+F Population Size: 38 Sources: Page: p.2648 |
Granulocytopenia | grade 4, 21% | 100 mg/m2 1 times / 3 weeks multiple, intravenous Studied dose Dose: 100 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / 3 weeks Co-administed with:: dexamethasone, p.o(40 mg/day, days 1–4) Sources: Page: p.2648 |
unhealthy, 63 n = 38 Health Status: unhealthy Condition: Multiple myeloma Age Group: 63 Sex: M+F Population Size: 38 Sources: Page: p.2648 |
Thrombocytopenia | grade 4, 8% | 100 mg/m2 1 times / 3 weeks multiple, intravenous Studied dose Dose: 100 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / 3 weeks Co-administed with:: dexamethasone, p.o(40 mg/day, days 1–4) Sources: Page: p.2648 |
unhealthy, 63 n = 38 Health Status: unhealthy Condition: Multiple myeloma Age Group: 63 Sex: M+F Population Size: 38 Sources: Page: p.2648 |
Cardiotoxicity | Disc. AE | 50 mg/m2 1 times / 4 weeks multiple, intravenous Recommended Dose: 50 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 50 mg/m2, 1 times / 4 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Ovarian Cancer Sources: Page: p.1 |
Congestive heart failure | Disc. AE | 50 mg/m2 1 times / 4 weeks multiple, intravenous Recommended Dose: 50 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 50 mg/m2, 1 times / 4 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Ovarian Cancer Sources: Page: p.1 |
Hepatic impairment | Disc. AE | 50 mg/m2 1 times / 4 weeks multiple, intravenous Recommended Dose: 50 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 50 mg/m2, 1 times / 4 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Ovarian Cancer Sources: Page: p.1 |
Infusion related reaction | acute Disc. AE |
50 mg/m2 1 times / 4 weeks multiple, intravenous Recommended Dose: 50 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 50 mg/m2, 1 times / 4 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Ovarian Cancer Sources: Page: p.1 |
Reaction anaphylactic anaphylactoid | grade 3-5 Disc. AE |
50 mg/m2 1 times / 4 weeks multiple, intravenous Recommended Dose: 50 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 50 mg/m2, 1 times / 4 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Ovarian Cancer Sources: Page: p.1 |
Myelosuppression | severe Disc. AE |
50 mg/m2 1 times / 4 weeks multiple, intravenous Recommended Dose: 50 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 50 mg/m2, 1 times / 4 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Ovarian Cancer Sources: Page: p.1 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [IC50 203 uM] | ||||
yes [Ki 49.4 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/12859862/ |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Myocardial injury produced by antineoplastic drugs. | 1975 |
|
Endomyocardial fibrosis associated with daunorubicin therapy. | 1976 Aug |
|
The cardiotoxicity of adriamycin and daunomycin in children. | 1976 Feb |
|
Tumorigenicity in vivo and induction of malignant transformation and mutagenesis in cell cultures by adriamycin and daunomycin. | 1976 Jun |
|
Daunorubicin-induced cardiotoxicity. | 1976 Mar |
|
Letter: Pericarditis in a case of early daunorubicin cardiomyopathy. | 1976 Sep |
|
Bradycardia due to anthracyclines. | 1992 Oct 3 |
|
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. | 2000 |
|
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. | 2000 Aug 1 |
|
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission. | 2000 Jul |
|
Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group. | 2000 Jul |
|
Chest and back pain associated with a six-hour infusion of liposomal daunorubicin. | 2000 Jun |
|
Anthracycline induced cardiomyopathy: successful treatment with angiotensin converting enzyme inhibitors. | 2000 May |
|
[Severe hemolysis and SIADH-like symptoms induced by vincristine in an ALL patient with liver cirrhosis]. | 2000 Nov |
|
Prevention by dexrazoxane of down-regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the rat. | 2000 Sep |
|
Daunorubicin attenuates tumor necrosis factor-alpha-induced biosynthesis of plasminogen activator inhibitor-1 in human umbilical vein endothelial cells. | 2001 Apr 23 |
|
Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. | 2001 Feb |
|
Down-regulation of catalase gene expression in the doxorubicin-resistant AML subline AML-2/DX100. | 2001 Feb 16 |
|
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. | 2001 Jul 1 |
|
Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome. | 2001 Jun 15 |
|
Effect of aging on cardiac contractility in a rat model of chronic daunorubicin cardiotoxicity. | 2002 |
|
Correlation of histopathological and biochemical appraisal of anthracyclin-induced myocardium damage. | 2002 |
|
Effects of dietary lipids on daunomycin-induced nephropathy in mice: comparison between cod liver oil and soybean oil. | 2002 Apr |
|
Reversible vincristine-related flaccid paralysis in a child with acute lymphoblastic leukemia. | 2002 Aug |
|
Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin. | 2002 Aug |
|
Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits. | 2002 Dec |
|
Comparison of anthracycline-induced death of human leukemia cells: programmed cell death versus necrosis. | 2002 Dec |
|
Determination of free and liposome-associated daunorubicin and daunorubicinol in plasma by capillary electrophoresis. | 2002 Dec 6 |
|
Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study. | 2002 Feb |
|
Monitoring daunorubicin-induced alterations in protein expression in pancreas carcinoma cells by two-dimensional gel electrophoresis. | 2002 Jun |
|
Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells. | 2002 Jun |
|
Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells. | 2002 May |
|
Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. | 2002 Nov |
|
Resistance of bcr-abl-positive acute lymphoblastic leukemia to daunorubicin is not mediated by mdr1 gene expression. | 2002 Nov |
|
Induction of metallothionein by zinc protects from daunorubicin toxicity in rats. | 2002 Sep 30 |
|
High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia. | 2003 |
|
Multiple alterations of canalicular membrane transport activities in rats with CCl(4)-induced hepatic injury. | 2003 Apr |
|
Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. | 2003 Dec 1 |
|
Different effects of metabolic inhibitors and cyclosporin A on daunorubicin transport in leukemia cells from patients with AML. | 2003 Feb |
|
Vincristine neurotoxicity in the presence of hereditary neuropathy. | 2003 Jan |
|
Safety of high-dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia. | 2003 Jul |
|
Daunorubicin-induced variations in gene transcription: commitment to proliferation arrest, senescence and apoptosis. | 2003 Jun 15 |
|
The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia. | 2003 Mar |
|
Efficacy and toxicity of liposomal daunorubicin included in PVABEC regimen for aggressive NHL of the elderly. | 2003 Mar |
|
[Successful treatment after acute promyelocytic leukemia (APL) syndrome of relapsed API with arsenic trioxide]. | 2003 Mar |
|
Cloning and functional characterization of the multidrug resistance-associated protein (MRP1/ABCC1) from the cynomolgus monkey. | 2003 Mar |
|
From conventional to stealth liposomes: a new frontier in cancer chemotherapy. | 2003 May-Jun |
|
Neurotoxicity of intrathecal methotrexate: MR imaging findings. | 2003 Oct |
|
Population pharmacokinetics of liposomal daunorubicin in children. | 2003 Oct |
|
Human intestinal absorption of imidacloprid with Caco-2 cells as enterocyte model. | 2004 Jan 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/daunorubicin.html
Usual Adult Dose for Acute Nonlymphocytic Leukemia: Under 60 years of age: 45 mg/m2 IV over 2 to 5 minutes once a day on days 1, 2, and 3 for the first course and on days 1 and 2 for subsequent courses) with cytosine arabinoside (ara-C) intravenously once a day (usually for 7 days for the first course and 5 days for subsequent courses) as remission induction therapy.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28381182
In order to determine the viability of HL-60, K562, THP-1, and HEK293T cells, they were trypsinized, counted, and seeded into 96-well plates and were treated with serial dilutions (0.0001, 0.001, 0.01, 0.1, 1 mkM) of DNR (Daunorubicin). Cell viability was determined 48 h after DNR treatment using the luminescent cell viability assay (Promega) through luminescence testing by BMG NOVOstar machine.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:42:03 UTC 2023
by
admin
on
Wed Jul 05 23:42:03 UTC 2023
|
Record UNII |
ZS7284E0ZP
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175414
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
||
|
NCI_THESAURUS |
C1594
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
||
|
FDA ORPHAN DRUG |
265808
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
||
|
WHO-ATC |
L01DB02
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
||
|
NDF-RT |
N0000007530
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.2
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
||
|
WHO-ATC |
L01XY01
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
||
|
NDF-RT |
N0000000176
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
||
|
NDF-RT |
N0000007530
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
||
|
LIVERTOX |
NBK548259
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
||
|
NDF-RT |
N0000007530
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/11/942
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
||
|
WHO-VATC |
QL01DB02
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5095
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
2257
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
SUB06917MIG
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
DAUNORUBICIN
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
CHEMBL178
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
DB00694
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
30323
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
DTXSID7022883
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
C62091
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
D003630
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
7063
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
ZS7284E0ZP
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
83142
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
M4104
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | Merck Index | ||
|
ZS7284E0ZP
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
100000086006
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
20830-81-3
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
41977
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
3109
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | RxNorm | ||
|
786
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
244-069-7
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY | |||
|
64677
Created by
admin on Wed Jul 05 23:42:03 UTC 2023 , Edited by admin on Wed Jul 05 23:42:03 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> SUBSTRATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||